Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Phase II randomized multicenter trial to compare Epirubicin and Cyclophosphamide plus
Docetaxel and Trastuzumab with Epirubicin and Cyclophosphamide plus Docetaxel and Lapatinib
for patients with positive HER2 and resectable or locally advanced breast cancer.